The development of androgen-independent prostate cancer

By B. Feldman, D. Feldman. Nature Reviews. Cancer, 2001

2,409 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7cabee1a6f8597ad7b999f4e40c6cab607291fd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009, background): “…initially lead to disease regression, in general, advanced prostate cancer ultimately progresses to an androgen-independent (AIPC) late stage that is refractory to current therapies (also termed ‘‘castration-resistant prostate cancer’’) (Debes and Tindall, 2004; Feldman and Feldman, 2001).”
Integrative molecular concept modeling of prostate cancer progression (2007, background): “Hormone-refractory metastatic cancers select for mechanisms to maintain androgen signaling (such as androgen receptor amplifications or mutation”
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion (2009, background): “Upon ligand interaction, the AR homodimerizes, undergoing phosphorylation and translocation to the nucleus, where it binds androgen response elements and induces transcription of target genes involved in cell-cycle regulation and proliferation ( Figure 1 )”
In vitro molecular mechanisms of bisphenol A action. (2007, background): “is initially highly effective, within 2–3 years of therapy most patients develop ADT-resistant tumors, for which no effective treatment is available [127,128].”
Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012, neutral): “Diarrhea 171 (21) 9 (1) 70 (18) 1 (<1)”
The Connectivity Map: a new tool for biomedical research (2007, background): “Motivated by the importance of AR signalling in prostate cancer, and specifically, the paucity of effective therapeutic approaches to hormone-refractory diseas”
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (2004, background): “6,9 An alternative model for therapy resistance suggests that recruitment of non-steroid receptor signal transduction pathways can activate the androgen response in the setting of clinical androgen deprivation.”
A history of prostate cancer treatment (2002, background): “Cytotoxic chemotherapy Many patients initially respond to androgen-ablative therapy but, with time, develop fatal androgen-independent diseas”
G-protein-coupled receptors and cancer (2007, background): “These steroid hormones activate their cognate androgen and oestrogen receptors ( AR and ER ), which are transcription factors of the nuclear hormone receptor famil”